GlassScriptPhysician profile
Charlton D Barber
NPI 1124607783
$4,090.50
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $1,407 · 2023: $1,668 · 2024: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.16 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.24 | 2021-2024 | |
| Janssen Biotech, INC. | $652.59 | 2021-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.25 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $419.19 | 2021-2024 | Entyvio, Gattex |
| Qol Medical, LLC | $315.75 | 2021-2023 | Sucraid |
| Celgene Corporation | $188.34 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $166.00 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Intercept Pharmaceuticals, INC. | $131.63 | 2021-2023 | Ocaliva |
| Pfizer INC. | $129.18 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $102.83 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $100.58 | 2021-2023 | Dificid |
| Genzyme Corporation | $84.51 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $74.56 | 2023 | Linzess |
| Evoke Pharma, INC. | $71.88 | 2021-2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $70.91 | 2023 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.95 | 2021-2022 | |
| Ardelyx, INC. | $55.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $49.11 | 2022 | |
| Braintree Laboratories, INC. | $38.30 | 2023 | Suflave |
| Olympus America INC. | $34.78 | 2022-2023 | Evis Exera III Video System Center |
| Novo Nordisk INC | $21.26 | 2024 | Rybelsus, Ozempic |
| Vivus LLC | $20.33 | 2021 | |
| Daiichi Sankyo INC. | $18.89 | 2021 | |
| Exact Sciences Corporation | $14.10 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $13.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlton Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.